The percentages of that cohort’s mCRC patients with concurrent mutations in KRAS, APC, and TP53, concurrent mutations in KRAS and APC, or concurrent mutations in KRAS and TP53 in tumor tissues were 19.8% (218/1099), 12.6% (138/1099), and 4.1%, respectively (Figure 1). This evidence concerns the gene APC and neoplasm.